Trial of EXenatide in Acute Ischaemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 350 participants.

Also called NCT03287076

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 350 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03287076
  • EudraCT 2018-004325-88
Other papers using this trial's data
  • Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial Stroke, 2023-12 DOI, PubMed 38011235, PMC10664794 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, Finland, New Zealand (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03287076. Randomized; single masking; primary purpose treatment. Start 2017-11-23 (actual); primary completion 2021-10-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial of EXenatide in Acute Ischaemic Stroke
Acronym
TEXAIS
Condition
Acute Ischemic Stroke
Intervention (Drug)
Exenatide Injection
Lead sponsor
Neuroscience Trials Australia (class: other)
Collaborator
National Health and Medical Research Council, Australia (class: other)
Collaborator
Monash University (class: other)

Record details

Record id
cardio:ct-nct03287076
Content hash
645a0caa8d380d28aec0d63b6eb3ec86b0bab3762fe5c0c069fb897363237ec7